Daridorexant in treatment refractory cluster headache: A retrospective case series
Headache: The Journal of Head and Face Pain · 16.11.2026
DOI: 10.1111/head.70196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 16.11.2026. Verfasst von Giacomo Querzola und 5 weiteren Autor:innen. Beteiligte Einrichtung: Stroke Unit, Neurology Department, Headache Center, San Carlo Borromeo Hospital (ASST Santi Paolo e Carlo), Milan, Italy. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives/Background Cluster headache (CH) is one of the most excruciating pain conditions known in humans. Most patients experience nocturnal attacks, which further worsen sleep quality and overall quality of life. The management of CH includes acute and preventive treatments, and in some cases, transitional therapy with corticosteroids may be used to achieve pain freedom in a shorter time while giving preventive therapy. We report our preliminary experience with daridorexant, a selective dual orexin receptor antagonist approved for chronic insomnia, as an adjunctive treatment in patients with treatment refractory CH, nocturnal attacks, and bad quality of sleep. Our objective was to describe within‐patient changes in nocturnal attack frequency, sleep quality, and headache‐related disability before and after add‐on daridorexant in refractory CH.
Methods
In this single‐center, retrospective before–after case series, we reviewed clinical data from 10 patients followed at the Headache Center of the San Carlo Borromeo Hospital in Milan (Italy) between June 2023 and December 2024, with a diagnosis of either episodic or chronic CH, who experienced nocturnal attacks, sleep disturbances, and with inadequate response to standard treatments, including verapamil, lithium, or corticosteroids. In these patients, daridorexant was administered as add‐on therapy, to treat the chronic insomnia. The frequency and features of CH attacks, sleep quality, headache‐related disability, and quality‐of‐life evaluations were assessed before and after treatment.
Results
Treatment with daridorexant was associated with a significant reduction in nocturnal attacks, from 13.1 ± 7.5 to 6.4 ± 7.7 attacks per week ( p < 0.050; n = 10/10). Patients also reported improved quality of life, with mean subjective quality‐of‐life scores increasing from 37% ± 15.6% to 61% ± 20.4% ( p = 0.001; n = 10/10). Headache‐related impact was reduced, with mean Headache Impact Test 6 scores decreasing from 62.0 ± 7.4 to 48.8 ± 16.2 ( p < 0.050; n = 10/10). In addition, no patient reported worsening on the Patient Global Impression of Change scale, and eight of the nine out of 10 available Patient Global Impression of Change ratings indicated improvement. Daridorexant was generally well‐tolerated, with adverse events reported in three out of 10 patients (30%), leading to treatment discontinuation in one patient.
Conclusion
Daridorexant was significantly associated particularly with a reduction in the number of nocturnal attacks in patients with CH refractory to conventional therapies. These pilot preliminary results suggest a potential role for daridorexant as an adjunctive option for patients with CH, particularly those with a poor response to traditional therapies, nocturnal attacks, and sleep disturbances. Further prospective, controlled studies are warranted to confirm these findings and clarify the mechanisms underlying the observed clinical benefits.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Stroke Unit, Neurology Department, Headache Center, San Carlo Borromeo Hospital (ASST Santi Paolo e Carlo), Milan, Italy.
ORCID-Profile: Giacomo Querzola
Zitieren
APA
Querzola, G., Galli, A., Altavilla, R., Mauri, M. A. M., Robotti, M., & Frediani, F. (2026). Daridorexant in treatment refractory cluster headache: A retrospective case series. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.70196
Vancouver
Querzola G, Galli A, Altavilla R, Mauri MAM, Robotti M, Frediani F. Daridorexant in treatment refractory cluster headache: A retrospective case series. Headache: The Journal of Head and Face Pain. 2026. doi:10.1111/head.70196
BibTeX
@article{Querzola2026,
author = {Querzola, Giacomo and Galli, Alberto and Altavilla, Riccardo and Mauri, Michela Anna Maria and Robotti, Micaela and Frediani, Fabio},
title = {Daridorexant in treatment refractory cluster headache: A retrospective case series},
journal = {Headache: The Journal of Head and Face Pain},
year = {2026},
doi = {10.1111/head.70196}
}
EUVIMED